Literature DB >> 18974392

Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate.

James D Orth1, Yangzhong Tang, Jade Shi, Clement T Loy, Christiane Amendt, Claudia Wilm, Frank T Zenke, Timothy J Mitchison.   

Abstract

Kinesin-5 inhibitors (K5I) are promising antimitotic cancer drug candidates. They cause prolonged mitotic arrest and death of cancer cells, but their full range of phenotypic effects in different cell types has been unclear. Using time-lapse microscopy of cancer and normal cell lines, we find that a novel K5I causes several different cancer and noncancer cell types to undergo prolonged arrest in monopolar mitosis. Subsequent events, however, differed greatly between cell types. Normal diploid cells mostly slipped from mitosis and arrested in tetraploid G(1), with little cell death. Several cancer cell lines died either during mitotic arrest or following slippage. Contrary to prevailing views, mitotic slippage was not required for death, and the duration of mitotic arrest correlated poorly with the probability of death in most cell lines. We also assayed drug reversibility and long-term responses after transient drug exposure in MCF7 breast cancer cells. Although many cells divided after drug washout during mitosis, this treatment resulted in lower survival compared with washout after spontaneous slippage likely due to chromosome segregation errors in the cells that divided. Our analysis shows that K5Is cause cancer-selective cell killing, provides important kinetic information for understanding clinical responses, and elucidates mechanisms of drug sensitivity versus resistance at the level of phenotype.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18974392      PMCID: PMC2597169          DOI: 10.1158/1535-7163.MCT-08-0684

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  23 in total

1.  Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen.

Authors:  T U Mayer; T M Kapoor; S J Haggarty; R W King; S L Schreiber; T J Mitchison
Journal:  Science       Date:  1999-10-29       Impact factor: 47.728

2.  Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1.

Authors:  P R Andreassen; O D Lohez; F B Lacroix; R L Margolis
Journal:  Mol Biol Cell       Date:  2001-05       Impact factor: 4.138

Review 3.  Microtubules as a target for anticancer drugs.

Authors:  Mary Ann Jordan; Leslie Wilson
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

4.  An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis.

Authors:  Weikang Tao; Victoria J South; Ronald E Diehl; Joseph P Davide; Laura Sepp-Lorenzino; Mark E Fraley; Kenneth L Arrington; Robert B Lobell
Journal:  Mol Cell Biol       Date:  2006-11-13       Impact factor: 4.272

5.  Potentiation of kinesin spindle protein inhibitor-induced cell death by modulation of mitochondrial and death receptor apoptotic pathways.

Authors:  Ulka Vijapurkar; Wei Wang; Ronald Herbst
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

6.  c-MYC delays prometaphase by direct transactivation of MAD2 and BubR1: identification of mechanisms underlying c-MYC-induced DNA damage and chromosomal instability.

Authors:  Antje Menssen; Alexey Epanchintsev; Dmitri Lodygin; Nousin Rezaei; Peter Jung; Berlinda Verdoodt; Joachim Diebold; Heiko Hermeking
Journal:  Cell Cycle       Date:  2007-02-03       Impact factor: 4.534

7.  Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5.

Authors:  Jue Shi; James D Orth; Tim Mitchison
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 8.  Diagnosing and exploiting cancer's addiction to blocks in apoptosis.

Authors:  Anthony G Letai
Journal:  Nat Rev Cancer       Date:  2008-02       Impact factor: 60.716

9.  Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.

Authors:  Charles Swanton; Michela Marani; Olivier Pardo; Patricia H Warne; Gavin Kelly; Erik Sahai; Frédéric Elustondo; Jenny Chang; Jillian Temple; Ahmed A Ahmed; James D Brenton; Julian Downward; Barbara Nicke
Journal:  Cancer Cell       Date:  2007-06       Impact factor: 31.743

10.  Examining the link between chromosomal instability and aneuploidy in human cells.

Authors:  Sarah L Thompson; Duane A Compton
Journal:  J Cell Biol       Date:  2008-02-18       Impact factor: 10.539

View more
  54 in total

1.  Microfluidics-integrated time-lapse imaging for analysis of cellular dynamics.

Authors:  Dirk R Albrecht; Gregory H Underhill; Joshua Resnikoff; Avital Mendelson; Sangeeta N Bhatia; Jagesh V Shah
Journal:  Integr Biol (Camb)       Date:  2010-03-19       Impact factor: 2.192

Review 2.  Mitosis in vertebrates: the G2/M and M/A transitions and their associated checkpoints.

Authors:  Conly L Rieder
Journal:  Chromosome Res       Date:  2011-04       Impact factor: 5.239

Review 3.  In vivo imaging in cancer.

Authors:  John Condeelis; Ralph Weissleder
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-09-22       Impact factor: 10.005

4.  High-throughput protease activity cytometry reveals dose-dependent heterogeneity in PMA-mediated ADAM17 activation.

Authors:  Lidan Wu; Allison M Claas; Aniruddh Sarkar; Douglas A Lauffenburger; Jongyoon Han
Journal:  Integr Biol (Camb)       Date:  2015-04-02       Impact factor: 2.192

Review 5.  Mitotic catastrophe: a mechanism for avoiding genomic instability.

Authors:  Ilio Vitale; Lorenzo Galluzzi; Maria Castedo; Guido Kroemer
Journal:  Nat Rev Mol Cell Biol       Date:  2011-04-29       Impact factor: 94.444

Review 6.  Measuring and modeling apoptosis in single cells.

Authors:  Sabrina L Spencer; Peter K Sorger
Journal:  Cell       Date:  2011-03-18       Impact factor: 41.582

Review 7.  Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic.

Authors:  Jue Shi; Timothy J Mitchison
Journal:  Endocr Relat Cancer       Date:  2017-03-01       Impact factor: 5.678

Review 8.  Kinesin-5: cross-bridging mechanism to targeted clinical therapy.

Authors:  Edward J Wojcik; Rebecca S Buckley; Jessica Richard; Liqiong Liu; Thomas M Huckaba; Sunyoung Kim
Journal:  Gene       Date:  2013-08-14       Impact factor: 3.688

Review 9.  Non-genetic cell-to-cell variability and the consequences for pharmacology.

Authors:  Mario Niepel; Sabrina L Spencer; Peter K Sorger
Journal:  Curr Opin Chem Biol       Date:  2009-10-14       Impact factor: 8.822

10.  An intermittent live cell imaging screen for siRNA enhancers and suppressors of a kinesin-5 inhibitor.

Authors:  Melody Tsui; Tiao Xie; James D Orth; Anne E Carpenter; Stewart Rudnicki; Suejong Kim; Caroline E Shamu; Timothy J Mitchison
Journal:  PLoS One       Date:  2009-10-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.